Compare KeyCorp (KEY) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KeyCorp vs Zoetis Inc — how do they compare? KeyCorp trades at $19.98 (market cap $21.45B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is the larger of the two by market cap, and KeyCorp pays the higher dividend (4.08%). Which is the better fit depends on your goals — on Pluang, investors hold KeyCorp for 66 Days and Zoetis Inc for 70 Days on average.
| KEY | ZTS | |
|---|---|---|
Market Cap | $21.45B | $30.20B |
Volume | 19,450,846 | 6,175,327 |
Sector | Financials | Health |
52-Week High | $23.99 | $147.53 |
52-Week Low | $16.78 | $69.09 |
Typical Hold Time | 66 Days | 70 Days |
Enterprise Value | $34.63B | $37.76B |
Dividend Yield | 4.08% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KeyCorp (KEY) trades at $19.97, up 0.71% with strong recent earnings beats and a 60.79% analyst buy rating. The stock shows bearish technical signals but maintains solid fundamentals with 26.72% net margin and 11.01% ROE. Recent corporate actions include a $0.21 dividend and executive appointments, while cash flow trends show operational stability despite recent net outflows.
KEY presents a compelling value opportunity with 25% upside to consensus target, supported by earnings momentum and dividend stability. Risks include technical bearish pressure, interest rate sensitivity, and competitive dividend landscape. The bank's improved 2026 revenue guidance and institutional accumulation suggest underlying strength despite near-term headwinds.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
